Oppenheimer Holdings, Inc. Reiterates $51.00 Price Target for Urogen Pharma (URGN)
Oppenheimer Holdings, Inc. set a $51.00 target price on Urogen Pharma (NASDAQ:URGN) in a research report released on Tuesday, Marketbeat Ratings reports. The firm currently has an outperform rating on the stock. Oppenheimer Holdings also issued estimates for Urogen Pharma’s Q4 2017 earnings at ($0.67) EPS, FY2017 earnings at ($2.05) EPS, FY2018 earnings at ($2.60) EPS, FY2019 earnings at ($1.79) EPS, FY2020 earnings at $0.99 EPS and FY2021 earnings at $3.82 EPS.
URGN has been the subject of a number of other reports. Zacks Investment Research downgraded shares of Urogen Pharma from a buy rating to a hold rating in a research note on Friday, August 18th. Jefferies Group LLC increased their price target on shares of Urogen Pharma from $27.00 to $37.00 and gave the company a buy rating in a report on Monday, October 9th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $36.80.
Urogen Pharma (NASDAQ:URGN) traded up $0.75 during mid-day trading on Tuesday, reaching $41.00. 176,311 shares of the company traded hands, compared to its average volume of 62,480. Urogen Pharma has a 1 year low of $13.01 and a 1 year high of $44.63.
ILLEGAL ACTIVITY WARNING: “Oppenheimer Holdings, Inc. Reiterates $51.00 Price Target for Urogen Pharma (URGN)” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://theolympiareport.com/2017/11/17/oppenheimer-holdings-inc-reiterates-51-00-price-target-for-urogen-pharma-urgn.html.
Hedge funds have recently added to or reduced their stakes in the company. FMR LLC bought a new position in Urogen Pharma during the second quarter worth $13,892,000. Menora Mivtachim Holdings LTD. grew its holdings in shares of Urogen Pharma by 341.4% during the third quarter. Menora Mivtachim Holdings LTD. now owns 569,589 shares of the company’s stock valued at $17,953,000 after buying an additional 440,534 shares during the last quarter. DSAM Partners London Ltd acquired a new position in shares of Urogen Pharma during the third quarter valued at about $2,348,000. Shikiar Asset Management Inc. acquired a new position in shares of Urogen Pharma during the third quarter valued at about $665,000. Finally, Alps Advisors Inc. acquired a new position in shares of Urogen Pharma during the second quarter valued at about $195,000. 40.55% of the stock is owned by hedge funds and other institutional investors.
About Urogen Pharma
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.